We are live on
!
Find out more
GC
Grace Capital Portfolio holdings
AUM
$168M
1-Year Est. Return
21.6%
This Fund
S&P 500
This Quarter
Est. Return
+5.41%
1 Year Est. Return
+21.6%
3 Year Est. Return
+126.68%
5 Year Est. Return
+161.89%
10 Year Est. Return
–
AUM
$262M
AUM Growth
+$74.2M
(+40%)
Cap. Flow
+$60.4M
Cap. Flow
% of AUM
23.06%
Top 10 Holdings %
Top 10 Hldgs %
27.97%
Holding
236
New
148
Increased
23
Reduced
45
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$8.58M |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$7.26M |
| 3 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$5.88M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$4.5M |
| 5 |
Visa
V
|
+$3.05M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Check Point Software Technologies
CHKP
|
+$4.78M |
| 2 |
Novartis
NVS
|
+$4.73M |
| 3 |
Citigroup
C
|
+$3.89M |
| 4 |
Enterprise Products Partners
EPD
|
+$3.74M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$3.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.43% |
| 2 | Technology | 18.17% |
| 3 | Financials | 14.51% |
| 4 | Consumer Discretionary | 9.11% |
| 5 | Energy | 7.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Pultegroup
PHM
$24B
| – | – |
-54,126
| Closed | -$1.55M |
|
227
Travelers Companies
TRV
$78.5B
| – | – |
-2,375
| Closed | -$325K |
|
|
TRHC
228
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| – | – |
-6,390
| Closed | -$234K |
|
|
TCP
229
DELISTED
TC Pipelines LP
TCP
| – | – |
-54,737
| Closed | -$1.84M |
|
Similar funds
REMS
TI
NM
KM
MC
FAC
MSO
ACM
Grace Capital's Q2 2018 Portfolio in Review
As of Q2 2018, Grace Capital held 236 positions worth $262M, up 40% from $188M the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Grace Capital deployed $60.4M of net new capital in Q2 2018, opening 148 new positions and adding to 23 existing holdings. Its largest new stake was MyoKardia, Inc. Common Stock: 177,304 shares worth $8.8M.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 13% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Citigroup, an estimated $3.89M trimmed.
- Grace Capital's largest Q2 2018 buy was MyoKardia, Inc. Common Stock: 177,304 shares worth $8.8M.
- Grace Capital added most to Meta Platforms (Facebook) in Q2 2018, an estimated $2.91M increase.
- Grace Capital's biggest Q2 2018 reduction was Citigroup, cutting an estimated $3.89M.
- Grace Capital fully exited Check Point Software Technologies in Q2 2018, selling an estimated $4.78M.
- Grace Capital's ten largest holdings make up 28% of its $262M portfolio in Q2 2018.
- Grace Capital opened 148 new positions and closed 16 in Q2 2018.
- Grace Capital's portfolio value rose 40% quarter-over-quarter to $262M.
Based on Grace Capital's 13F filing for Q2 2018, filed 15 Aug 2018.